Vital Signs - Avastin vs. Lucentis: Dollars and Sense

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on October 27, 2008, provides an strategic overview of issues surrounding the usage of Avastin and Lucentis in age-related macular degeneration (AMD) patients. Additionally, a company spotlight is provided for Pipex Pharmaceuticals, a developmental stage specialty pharmaceutical company focused on developing its proprietary drug candidates for the treatment of autoimmune diseases and disorders of the central nervous system. Reimbursement and regulatory news from the FDA is also provided for the week of October 13, 2008.

Table of Contents

Vital Signs - Avastin vs. Lucentis: Dollars and SenseVital Signs: 27 October 2008This week's issue:




Related Research

Release Date : 26-Sep-17

Region : North America

Release Date : 25-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.